1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma
    Review

    Abramson, J. S.; Stuver, R.; Herrera, A.; Patterson, E.; Wen, Y. P.; Moskowitz, A.
    Critical Reviews in Oncology/Hematology (2024)

    Fulltext@MSK | Save
  • Seven-year overall survival analysis from ECHELON-1 study of A+ AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma
    Meeting Abstract

    Ansell, S. M.; Straus, D. J.; Connors, J. M.; Jurczak, W.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Kumar, A.; Hill, B. T.; Bond, D. A.; Kahl, B. S.; Danilov, A. V.; Merryman, R.; Grover, N. S.; Tun, A. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M. K.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL)
    Meeting Abstract

    Reguera, J. L.; Garcia-Sancho, A. M.; Kuruvilla, J.; Izutsu, K.; Barbui, A. M.; Peter, B.; Mielke, S.; Palomba, M. L.; Cartron, G.; Ghesquieres, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP)
    Meeting Abstract

    Till, B. G.; Jacobson, C. A.; Palomba, M. L.; Abramson, J. S.; Arnason, J.; Locke, F. L.; Caimi, P. F.; Grover, N. S.; Karmali, R.; Suh, H. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
    Meeting Abstract

    Winter, A. M.; Bharadwaj, S.; Herrera, A. F.; Iragavarapu, C.; Mirza, S.; Palomba, M. L.; Patel, S. S.; Gharibo, M. M.; Bernasconi, D.; Krimmel, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study
    Meeting Abstract

    Iyer, S. P.; Jagadeesh, D.; Domingo-Domenech, E.; Benedetti, F.; Izquierdo, A. R.; Bouabdallah, K.; Vitolo, U.; Illidge, T. M.; Liu, J.; Shaikh, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights
    Meeting Abstract

    Keane, F.; Tuli, R.; O'Connor, C. A.; Schwartz, C.; Park, W.; Varghese, A. M.; Perry, M.; Singhal, A.; Vardhana, S.; Hendifar, A. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • What is the best salvage therapy for Hodgkin lymphoma?
    Review

    Luttwak, E.; Moskowitz, A. J.
    Current Opinion in Oncology (2024)

    Fulltext@MSK | Save